Wavelight announces two IOL approvals

Article

Wavelight has announced the receipt of two regulatory approvals for its intraocular lenses (IOLs), thus expanding its intraocular product range.

Wavelight has announced the receipt of two regulatory approvals for its intraocular lenses (IOLs), thus expanding its intraocular product range.

The first approval was for the Lentis L-403 lens, which has a very large optic and is made of the company?s proprietary HydroSmart acrylic material. This lens is particularly recommended for anterior segment procedures.

Although the firm admits that it will continue to supply its existing, hydrophilic lenses to customers, it is focusing much of its attention on lenses made of the advanced acrylic materials, which contain very sharp, square edges.

The second approval was for the company?s three-piece hydrophobic acrylic lens.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.